We don’t own Eli Lilly exclusively for its potential Alzheimer’s treatment. However, we still find Biogen’s topline data to be very encouraging for Lilly.
Source link: https://www.cnbc.com/2022/09/28/heres-why-biogens-promising-alzheimers-drug-data-is-also-good-news-for-eli-lilly-.html